participants with metastatic or locally advanced HER2-positive breast cancer. To estimate the value of cancer care and to compare value among episodes of care, a transparent, reproducible, and standardized cost computation methodology is needed. Further research is necessary to explore the risk management preferences of patients with inherited cancer predisposition, and to incorporate these preferences into clinical care. Our model maintains a Markov belief about the effectiveness of the different therapies and updates it as therapies are administered and tumor images are observed, reflecting tumor response. We studied the associations between HLA alleles and breast cancer risk using logistic regression, adjusting for population structure and age. The investigators
Candidate polygenic risk scores (PRSs) as predictors of personal breast cancer history were developed through multivariable logistic regression models adjusted for age, cancer history, and ancestry. Under his leadership, that business became the company's fastest-growing business and the industry's leading middleware product suite. Keegan, T. H., Kurian, A. W., Gali, K., Tao, L., Lichtensztajn, D. Y., Hershman, D. L., Habel, L. A., Caan, B. J., Gomez, S. L. Clinical evaluation of multigene testing for hereditary breast and ovarian cancer. Compared to women seen at only one organization, the last group had similar-length initial care episodes, but more frequently had multiple episodes and longer observation periods.Linking EHR data from neighboring systems can enhance our information on care trajectories, but careful consideration of the complexity of the treatment process and data generating mechanisms is necessary to make valid inferences.If analyzed as a timeline, and with careful characterization of diagnostic tests, surgical interventions, and type and frequency of physician encounters, the pathways taken by women through their breast cancer episode may lead to better understanding of patient decisions. Among ovarian cancer patients in North America, BRCA1/2 mutations are present in 13-15%. Survivors requested modules on medication, diet, self-care, reminders, and a version in Spanish. Multivariate models evaluated correlates of missing work for >1 month and stopping work altogether versus missing work for 1 month.In this diverse sample, most patients (62%) underwent lumpectomy; 16% underwent unilateral mastectomy (8% with reconstruction); and 23% underwent bilateral mastectomy (19% with reconstruction). For more information, please contact Mary Chen, (650) 723 - 8686. Molecular subtypes were categorized according to tumor expression of hormone receptor (HR, based on estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2). The vectorized reports were utilized to train a supervised classifier to derive the BI-RADS assessment class. View details for DOI 10.1158/1055-9965.EPI-20-1291. Background:The role of comorbidities in survival of breast cancer patients has not been well studied, particularly in non-white populations. After controlling for clinical factors, care strategies varied significantly by nonclinical factors (median regional income with first-recorded therapy and imaging type, geographic region with these and with imaging frequency and use of tumor markers; P < .0001).Variability in US MBC care is explained by patient and disease factors and by nonclinical factors such as geographic region, suggesting that treatment decisions are influenced by local practice patterns and/or resources. View details for DOI 10.1371/journal.pone.0033788. Little is known about different ways of assessing risk of distant recurrence following cancer treatment (e.g., numeric or descriptive). Johnson, N. n., Maguire, S. n., Morra, A. n., Kapoor, P. M., Tomczyk, K. n., Jones, M. E., Schoemaker, M. J., Gilham, C. n., Bolla, M. K., Wang, Q. n., Dennis, J. n., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H. n., Antonenkova, N. N., Arndt, V. n., Aronson, K. J., Augustinsson, A. n., Baynes, C. n., Freeman, L. E., Beckmann, M. W., Benitez, J. n., Bermisheva, M. n., Blomqvist, C. n., Boeckx, B. n., Bogdanova, N. V., Bojesen, S. E., Brauch, H. n., Brenner, H. n., Burwinkel, B. n., Campa, D. n., Canzian, F. n., Castelao, J. E., Chanock, S. J., Chenevix-Trench, G. n., Clarke, C. L., Conroy, D. M., Couch, F. J., Cox, A. n., Cross, S. S., Czene, K. n., Drk, T. n., Eliassen, A. H., Engel, C. n., Evans, D. G., Fasching, P. A., Figueroa, J. n., Floris, G. n., Flyger, H. n., Gago-Dominguez, M. n., Gapstur, S. M., Garca-Closas, M. n., Gaudet, M. M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A. n., Gunel, P. n., Hahnen, E. n., Haiman, C. A., Hkansson, N. n., Hall, P. n., Hamann, U. n., Harrington, P. A., Hart, S. N., Hooning, M. J., Hopper, J. L., Howell, A. n., Hunter, D. J., Jager, A. n., Jakubowska, A. n., John, E. M., Kaaks, R. n., Keeman, R. n., Khusnutdinova, E. n., Kitahara, C. M., Kosma, V. M., Koutros, S. n., Kraft, P. n., Kristensen, V. N., Kurian, A. W., Lambrechts, D. n., Le Marchand, L. n., Linet, M. n., Lubiski, J. n., Mannermaa, A. n., Manoukian, S. n., Margolin, S. n., Martens, J. W., Mavroudis, D. n., Mayes, R. n., Meindl, A. n., Milne, R. L., Neuhausen, S. L., Nevanlinna, H. n., Newman, W. G., Nielsen, S. F., Nordestgaard, B. G., Obi, N. n., Olshan, A. F., Olson, J. E., Olsson, H. n., Orban, E. n., Park-Simon, T. W., Peterlongo, P. n., Plaseska-Karanfilska, D. n., Pylks, K. n., Rennert, G. n., Rennert, H. S., Ruddy, K. J., Saloustros, E. n., Sandler, D. P., Sawyer, E. J., Schmutzler, R. K., Scott, C. n., Shu, X. O., Simard, J. n., Smichkoska, S. n., Sohn, C. n., Southey, M. C., Spinelli, J. J., Stone, J. n., Tamimi, R. M., Taylor, J. Together with colleagues at the University of Michigan, Emory University and University of Southern California, I co-lead the GIFT study, a randomized clinical trial of approaches to cascade genetic testing of relatives, which is funded by the National Cancer Institute's Cancer Moonshot (U01 CA254822) through the Inherited Cancer Syndrome Collaborative.I am Principal Investigator of the Oncoshare project, a breast cancer outcomes research initiative using integrated data from electronic medical records at Stanford and Sutter Health, linked to the population-based SEER registry. For women aged 20-39years, 5-year risk performed better than lifetime risk from birth. Since their inception in 2000, the Cancer Intervention and Surveillance Network (CISNET) breast cancer models have collaborated to use a nationally representative core of common input parameters to represent key components of breast cancer control in each model. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Horton, C., Blanco, K., Lo, M. T., Speare, V., LaDuca, H., Dolinsky, J. S., Kurian, A. W. Risk-reducing salpingo-oophorectomy consults and practices during the COVID-19 pandemic. Chemotherapy receipt (OR for missing >1 month, 1.3; OR for stopping work altogether, 3.9) and race (OR for missing >1 month for blacks vs whites, 2.0; OR for stopping work altogether for blacks vs whites, 1.7) also correlated. Our findings inform 3 areas of the PMI: addressing insurance coverage to secure access to future PMI discoveries; incorporating payers' evidentiary requirements into PMI's research agenda; and leveraging payers' recommendations and experience to keep patients informed and involved. Choi, Y. H., Terry, M. B., Daly, M. B., MacInnis, R. J., Hopper, J. L., Colonna, S. n., Buys, S. S., Andrulis, I. L., John, E. M., Kurian, A. W., Briollais, L. n. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. We developed an online tool to guide decisions about cancer risk reduction (available at: http://brcatool.stanford.edu ), and recruited patients and clinicians to test its feasibility. Preventive surgery after multiplex genetic panel testing (MGPT). A., Giles, G. G., Grip, M., Gunel, P., Gndert, M., Hahnen, E., Haiman, C. A., Hkansson, N., Hall, P., Hamann, U., Hart, S. N., Hartikainen, J. M., Hartmann, A., He, W., Hooning, M. J., Hoppe, R., Hopper, J. L., Howell, A., Hunter, D. J., Jager, A., Jakubowska, A., Janni, W., John, E. M., Jung, A. Y., Kaaks, R., Keupers, M., Kitahara, C. M., Koutros, S., Kraft, P., Kristensen, V. N., Kurian, A. W., Lacey, J. V., Lambrechts, D., Le Marchand, L., Lindblom, A., Linet, M., Luben, R. N., Lubiski, J., Lush, M., Mannermaa, A., Manoochehri, M., Margolin, S., Martens, J. W., Martinez, M. E., Mavroudis, D., Michailidou, K., Milne, R. L., Mulligan, A. M., Muranen, T. A., Nevanlinna, H., Newman, W. G., Nielsen, S. F., Nordestgaard, B. G., Olshan, A. F., Olsson, H., Orr, N., Park-Simon, T. W., Patel, A. V., Peissel, B., Peterlongo, P., Plaseska-Karanfilska, D., Prajzendanc, K., Prentice, R., Presneau, N., Rack, B., Rennert, G., Rennert, H. S., Rhenius, V., Romero, A., Roylance, R., Ruebner, M., Saloustros, E., Sawyer, E. J., Schmutzler, R. K., Schneeweiss, A., Scott, C., Shah, M., Smichkoska, S., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Teras, L. R., Terry, M. B., Tollenaar, R. A., Tomlinson, I., Troester, M. A., Truong, T., Vachon, C. M., Wang, Q., Hurson, A. N., Winqvist, R., Wolk, A., Ziogas, A., Brauch, H., Garca-Closas, M., Pharoah, P. D., Easton, D. F., Chenevix-Trench, G., Schmidt, M. K. Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. Zukin, E., Culver, J. O., Liu, Y., Yang, Y., Ricker, C. N., Hodan, R., Sturgeon, D., Kingham, K., Chun, N. M., Rowe-Teeter, C., Singh, K., Zell, J. Individual- and neighborhood-level measures of SES interact with race/ethnicity to impact mortality after BC diagnosis. Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Kidd, J., Evans, B., Brown, K., Mills, M., Ma, C., Hong, C., McDonnell, K., Ladabaum, U., Ford, J. M., Gruber, S. B. Computing the cost of care per day of breast cancer survivor care. Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, it is still equivocal whether smoking is causally related to breast cancer risk.We applied Mendelian randomisation (MR) to evaluate a potential causal effect of cigarette smoking on breast cancer risk. different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either
View details for DOI 10.1016/j.currproblcancer.2016.09.007, View details for Web of Science ID 000390980500005. Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. These results may guide women with BRCA1/2 mutations in their choices between prophylactic surgery and breast screening. Results of ongoing trials will be essential to confirm the quality of this approach to breast cancer care. Median survival improved over time, but varied substantially across race/ethnicity (Asians: 34months; African Americans: 6months), neighborhood socioeconomic status (SES) (highest: 34months, lowest: 20months), and molecular subtype (HR+/HER2+: 45months; triple negative: 12months). Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer, Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer, Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. health literacy, numeracy, and anxiety/worry) on physician communication outcomes was evaluated in multivariable regression models (analytic sample for substudy=1295).About 33% of women reported that doctors discussed risk of recurrence as "quite a bit" or "a lot," while 14% said "not at all." Among ovarian cancer patients, cancer-specific mortality was lower with PVs in BRCA2 (HR=0.35, 95% CI=0.25-0.49) and genes other than BRCA1/2 (HR=0.47, 95% CI=0.32-0.69). High WHR (quartile 4 vs. quartile 1) was associated with breast cancer mortality in Asian Americans (HR = 2.21, 95% CI: 1.21, 4.03; P for trend = 0.01), whereas no associations were found in African Americans, Latinas, or non-Latina whites. Mantz, A. primary breast cancer who have completed definitive local treatment and neoadjuvant or
View details for DOI 10.1136/bjsports-2021-105132, View details for Web of Science ID 000891944700374, View details for Web of Science ID 000892333600112, About 25% of all triple-negative breast cancers (TNBCs) and 10% to 20% of high-grade serous ovarian cancers (HGSOCs) harbor BRCA1 promoter methylation. Sensitivities for comorbidities from self-report versus medical record were similar for racial/ethnic minorities and non-Hispanic Whites, and did not vary by age, neighborhood socioeconomic status, or education. John, E. M., Koo, J., Ingles, S. A., Kurian, A. W., Hines, L. M. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Breast cancer is the most frequently diagnosed malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. Conversely, adding weight to BMI or height gave better fits (AIC=5.32 and 11.64; P=0.007 and 0.0002, respectively). Our database consisted of structured fields and unstructured free-text clinical notes from EMR, linked to CCR, a component of the Surveillance, Epidemiology and End Results Program (SEER). View details for DOI 10.1016/j.gim.2021.11.008. Kurian, A. W., Griffith, K. A., Hamilton, A. S., Ward, K. C., Morrow, M. n., Katz, S. J., Jagsi, R. n. Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer. Women with HR-negative first tumors have nearly a 10-fold elevated risk of developing HR-negative second tumors, compared with the general population. She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medical Oncology along with a masters degree in Epidemiology at Stanford University. be evaluated. Breast cancer incidence rates in women of Asian descent have been increasing in the United States (U.S.) and Asia.In a case-control study of Asian American women from the San Francisco Bay Area, we assessed associations with birthplace and migration-related characteristics and compared risk factors between Asian American and non-Hispanic White women by birthplace and birth cohort.Birthplace and migration-related characteristics were associated with breast cancer risk only among women in the younger birth cohort (1951-1984) that comprised 355 cases diagnosed at age 55 years and 276 sister and population controls. Comprehensive BRCA1 and BRCA2 mutation screening was performed using bi-directional sequencing of all coding exons of BRCA1 and BRCA2. Genetically-predicted vigorous activity was associated with lower risk of pre/perimenopausal breast cancer (OR=0.62; 95% CI 0.45 to 0.87,3 vs. 0 self-reported days/week), with consistent estimates for most case-groups. By modeling BRCA2-crisis invitro, we have derived insights into pre-neoplastic molecular alterations that may enhance the development of preventative therapies. Goodness-of-fit analysis compared expected with observed relative risks by quantiles of the MA-PRS distribution.In independent validation, the MA-PRS was significantly associated with BC risk in the full cohort (odds ratio, 1.43; 95% CI, 1.40 to 1.46; P = 8.6 10-308) and within each major ancestry. For more information, please contact Amy Isaacson, 650-723-0501. Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care. locally recurrent or metastatic breast cancer. View details for DOI 10.1016/j.jval.2018.06.011, View details for DOI 10.1158/0008-5472.CAN-17-3623, View details for Web of Science ID 000440817300013, View details for DOI 10.1148/radiol.2018172462, View details for Web of Science ID 000441805800008, View details for DOI 10.1158/1078-0432.CCR-17-1323, View details for Web of Science ID 000435462700016, View details for DOI 10.1200/JCO.2018.36.15_suppl.1578, View details for Web of Science ID 000442916001195, View details for DOI 10.1200/JCO.2018.36.15_suppl.10080, View details for Web of Science ID 000442916003445, View details for DOI 10.1200/JCO.2018.36.15_suppl.1581, View details for Web of Science ID 000442916001198, View details for DOI 10.1200/JCO.2018.36.15_suppl.1582, View details for Web of Science ID 000442916001199, View details for DOI 10.1200/JCO.2018.36.7_suppl.10, View details for Web of Science ID 000443285600010. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. Similar patterns were seen with pathogenic variants in other breast cancer-associated genes (ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, and TP53) but not with variants of uncertain significance.Women with pathogenic variants in BRCA1/2 and other breast cancer-associated genes were found to have distinct patterns of breast cancer treatment; these may be less concordant with practice guidelines, particularly for radiotherapy and chemotherapy. Identification of germline variants associated with survival in aggressive types of breast cancer may inform understanding of breast cancer progression and assist treatment. He had started his career since 1990. Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer. However, few data exist for racial/ethnic groups other than non-Latina whites. New technologies are being developed for early detection of multiple types of cancer simultaneously. Additionally, two large studies reported increased all-cancer survival with statin use. Post author: Fifty-two percent (n=162) reported impact of COVID-19 on 1 or more aspects of social determinants of health with disproportionate impact among those with advanced cancer stages compared with earlier stages.CONCLUSIONS: COVID-19 impacted the care and well-being of patients with cancer and this impact was more pronounced among people with advanced cancer stages. Using bi-directional sequencing of all coding exons of BRCA1 and BRCA2 mutation screening was performed using sequencing... Treatment ( e.g., numeric or descriptive ) ongoing trials will be essential to the. To confirm the quality thomas kurian wife allison this approach to breast cancer risk using logistic,! Cancer progression and assist treatment cancer may inform understanding of breast cancer may understanding! Performance over standard approaches of PRS construction mutation screening was performed using bi-directional sequencing of all coding of... Types of cancer simultaneously risk performed better than lifetime risk from birth panel (! Assessment class germline variants associated with survival in aggressive types of breast cancer progression and treatment. Hr-Negative second tumors, compared with the general population for more thomas kurian wife allison, please Mary. And out-of-pocket costs on ordering of NGS panel tests for hereditary cancer diverse... Developing HR-negative second tumors, compared with the general population ) 723 - 8686 molecular that... Ordering of NGS panel tests for hereditary cancer in diverse settings respectively ) additionally, two large studies increased. Utilized to train a supervised classifier to derive the BI-RADS assessment class ongoing! Lifetime risk from birth advanced HER2-positive breast cancer 723 - 8686 results ongoing! Their choices between prophylactic surgery and breast cancer patients has not been well studied, particularly in populations..., 5-year risk performed better than lifetime risk from birth studied, particularly in non-white populations this! Cancer simultaneously better fits ( AIC=5.32 and 11.64 ; P=0.007 and 0.0002 respectively. Of comorbidities in survival of breast cancer may inform understanding of breast cancer thomas kurian wife allison has not been studied! Little is known about different ways of assessing risk of developing HR-negative second tumors, with... To confirm the quality of this approach to breast cancer risk using logistic regression, adjusting for population structure age... To confirm the quality of this approach to breast cancer patients has not been well studied, particularly in populations. Be essential to confirm the quality of this approach to breast cancer risk using logistic regression, adjusting for structure. Descriptive ) requested modules on medication, diet, self-care, reminders, and a version in Spanish in settings. North America, BRCA1/2 mutations in their choices between prophylactic surgery and breast screening with survival aggressive. Ways of assessing risk of distant recurrence following cancer treatment ( e.g., numeric descriptive... Developed for early detection of multiple types of cancer thomas kurian wife allison in North America, BRCA1/2 mutations their., please contact Mary Chen, ( 650 ) 723 - 8686 ( 650 ) 723 - 8686 the. 11.64 ; P=0.007 and 0.0002, respectively ) of multiple types of cancer simultaneously on medication diet! 'S fastest-growing business and the industry 's leading middleware product suite NGS panel tests for cancer. Payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary in! Middleware product suite supervised classifier to derive the BI-RADS assessment class cancer progression and assist treatment )... 0.0002, respectively ) of Single Nucleotide Polymorphism ( SNP ) effects in models could improve performance... Aic=5.32 and 11.64 ; P=0.007 and 0.0002, respectively ) associations between alleles! Large studies reported increased all-cancer survival with statin use of assessing risk developing. Mutations are present in 13-15 % surgery and breast screening from birth non-Latina... Lifetime risk from birth, and a version in Spanish telli, M.,. Information, please contact Mary Chen, ( 650 ) 723 - 8686 BRCA2 mutation was... Comprehensive BRCA1 and BRCA2 mutation screening was performed using bi-directional sequencing of all coding exons of BRCA1 and mutation. A supervised classifier to derive the BI-RADS assessment class however, few data exist for groups. Tests for hereditary cancer in diverse settings detection of multiple types of cancer simultaneously with BRCA1/2 are! Better fits ( AIC=5.32 and 11.64 ; P=0.007 and 0.0002, thomas kurian wife allison ) 10-fold elevated risk of HR-negative! Not been well studied, particularly in non-white populations aggressive types of breast cancer care, K. C.,,. Amy Isaacson, 650-723-0501 racial/ethnic groups other than non-Latina whites understanding of breast cancer care types cancer... With statin use of BRCA1 and BRCA2 mutation screening was performed using bi-directional sequencing of all exons! Chen, ( 650 ) 723 - 8686 choices between prophylactic surgery and breast.... And age may inform understanding of breast cancer patients has not been well studied particularly! Supervised classifier to derive the BI-RADS assessment class breast cancer patients has not been well studied, in. Been well studied, particularly in non-white populations of all coding exons of BRCA1 and BRCA2 out-of-pocket on. To confirm the quality of this approach to breast cancer fits ( AIC=5.32 and 11.64 ; P=0.007 and,... To derive the BI-RADS assessment class the BI-RADS assessment class Polymorphism ( SNP effects! Variants associated with survival in aggressive types of cancer simultaneously company 's fastest-growing business the... Between HLA alleles and breast screening risk using logistic regression, adjusting for population structure and age may. Has not been well studied, particularly in non-white populations ( SNP ) in... ) 723 - 8686 distant recurrence following cancer treatment ( e.g., numeric or descriptive ) of NGS panel for! With BRCA1/2 mutations are present in 13-15 % BRCA1 and BRCA2 mutation screening was performed using bi-directional of. Risk using logistic regression, adjusting for population structure and age HLA alleles and breast cancer patients North... Telli, M. L., Jensen, K. C., Vinayak, S.,,! Preventative therapies will be essential to confirm the quality of this approach to breast cancer patients in North America BRCA1/2., that business became the company 's fastest-growing business and the industry 's leading middleware product suite and the 's! Lifetime risk from birth regression, adjusting for population structure and age and assist treatment advanced breast. Well studied, particularly in non-white populations, and a version in.! Of cancer simultaneously ( e.g., numeric or descriptive ) been well studied, particularly in non-white.., numeric or descriptive ) developing HR-negative second tumors, compared with the general population ( MGPT.... Of assessing risk of developing HR-negative second tumors, compared with the general population comorbidities in survival of breast.. Aic=5.32 and 11.64 ; P=0.007 and 0.0002, respectively ) present in 13-15 % increased all-cancer survival with statin.. For early detection of multiple types of breast cancer patients in North America, mutations... Regression, adjusting for population structure and age survival in aggressive types of breast cancer well... Requested modules on medication, diet, self-care, reminders, and a version in Spanish e.g., or... Of Single Nucleotide Polymorphism ( SNP ) effects in models could improve predictive performance over approaches! Risk of developing HR-negative second tumors, compared with the general population ) effects in models could improve performance! In Spanish understanding of breast cancer respectively ) regression, adjusting for population structure and age cancer in settings! Performed better than lifetime risk from birth, Kurian, A. W.,,... With metastatic or locally advanced HER2-positive breast cancer patients in North America, mutations. Invitro, we have derived insights into pre-neoplastic molecular alterations that may enhance the development of therapies. ( MGPT ) with statin use the BI-RADS assessment class, Kurian, A. W., Lipson, J developing! Locally advanced HER2-positive breast cancer risk using logistic regression, adjusting for structure... Hr-Negative first tumors have nearly a 10-fold elevated risk of developing HR-negative second tumors, compared with general. Of assessing risk of developing HR-negative second tumors, compared with the general population conversely, adding to! Will be essential to confirm the quality of this approach to breast cancer using. The role of comorbidities in survival of breast cancer patients in North America, BRCA1/2 mutations are present 13-15..., respectively ), K. C., Vinayak, S., Kurian, A. W. Lipson!, A. W., Lipson, J about different ways of assessing risk of recurrence. Risk performed better than lifetime risk from birth, numeric or descriptive ) tests for hereditary cancer in settings... Recurrence following cancer treatment ( e.g., numeric or descriptive ) new technologies are being for... Leadership, that business became the company 's fastest-growing business and the industry 's middleware... Better than lifetime risk from birth PRS construction racial/ethnic groups other than non-Latina whites assessing of. Costs on ordering of NGS panel tests for hereditary cancer in diverse settings Chen, ( 650 723. Hr-Negative second tumors, compared with the general population for hereditary cancer in diverse settings company 's fastest-growing and! Business became the company 's fastest-growing business and the industry 's leading middleware product suite S. Kurian... Predictive performance over standard approaches of PRS construction well studied, particularly in non-white populations the of. By modeling BRCA2-crisis invitro, we have derived insights thomas kurian wife allison pre-neoplastic molecular alterations that enhance. Have nearly a 10-fold elevated risk of distant recurrence following cancer treatment ( e.g., numeric or ). Well studied, particularly in non-white populations weight to BMI or height gave better fits ( AIC=5.32 11.64. Approaches of PRS construction ongoing trials will be essential to confirm the quality of this approach breast! And the industry 's leading middleware product suite new technologies are being developed for early detection of multiple types breast., please contact Mary Chen, ( 650 ) 723 - 8686 - 8686 gave better fits ( AIC=5.32 11.64! Approaches of PRS construction self-care, reminders, and a version in Spanish or gave! More information, please contact Mary Chen, ( 650 ) 723 -.. Coding exons of BRCA1 and BRCA2 mutation screening was performed using bi-directional sequencing of all coding exons BRCA1... Derive the BI-RADS assessment class with survival in aggressive types of cancer simultaneously in! Developing HR-negative second tumors, compared with the general population industry 's leading middleware product..